BOH-2C-B Stats & Data

Name clarity reduces substitution risk: BOHB (β‑hydroxy‑2C‑B) is distinct from BOB (β‑methoxy‑2C‑B) and from bk‑2C‑B (β‑keto‑2C‑B); community threads show ongoing confusion in vendor and user labeling. Reagent‑test every batch; 2C‑B look‑alikes (e.g., 25x‑NBOMe) and even dangerous stimulant + NBOMe mixtures have been sold as ‘2C‑B’, so treat any unlabeled powder or pill with caution and use multiple reagents. User timelines cluster around 50–65 mg oral for a moderate experience (~9 h), with 100–120 mg producing longer, stronger effects; several reports note migraine‑like headaches during the late comedown. Intranasal administration is widely reported as extremely painful (‘snorting glass’) with little to no efficacy advantage; prefer oral dosing. Because onset can be gradual and the experience long, avoid redosing during the first 3–4 h and space sessions by at least 2 weeks to limit tolerance and sleep disruption. General phenethylamine guidance applies: avoid combining with MAOIs and seizure‑threshold–lowering drugs (e.g., tramadol); keep hydration moderate with electrolytes if active; and prepare benzodiazepines only for emergency anxiety under sober supervision. Anecdotally, jaw clenching/bruxism occurs; some users find magnesium supplements helpful, but evidence is limited and dosing should stay within typical dietary ranges. Always measure with a 0.001 g scale (or carefully prepared volumetric dosing) and perform an allergy test on a tiny amount before a full dose.